Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 3/20 | 0.69 |
| ▸ | CCR7 | P32248 | 1/20 | 0.69 |
| ▸ | CXCR2 | P25025 | 18/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 16/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536950 | 1.00 | CCR6 (0.69) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803010 | 1.00 | CCR6 (0.69) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803068 | 0.98 | CCR6 (0.72) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL30536951 | 0.98 | CCR6 (0.72) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803066 | 0.98 | CCR6 (0.72) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL30536958 | 0.97 | CCR6 (0.67) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803111 | 0.97 | CCR6 (0.67) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803112 | 0.97 | CCR6 (0.67) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803016 | 0.89 | CCR6 (0.68) | CCR6CCR7CXCR2CXCR1CXCR3 | |
| SCHEMBL21803058 | 0.89 | CCR6 (0.68) | CCR6CCR7CXCR2CXCR1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2021-04-13 | — | — | US | claimed |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2020-03-26 | — | — | US | claimed |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CCR6 1/4885CCR7 19/4885CXCR2 13/4885 |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CCR6 1/4885CCR7 19/4885CXCR2 13/4885 |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CCR6 1/4885CCR7 19/4885CXCR2 13/4885 |
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CCR6 1/4885CCR7 19/4885CXCR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.